Market Insights and Stocks on the Move

January 30, 2025

DENVER, Colo., Jan 30, 2025 (247marketnews.com)- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial landscape.

Kazia Therapeutics (NASDAQ:KZIA) announced receiving regulatory approval for a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer, which it launched.

Alpha Modus (NASDAQ:AMOD) published a stated from its CEO, William Alessi. Alessi highlighted the company’s robust fundamentals, growth strategy, and commitment to delivering shareholder value.

“The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the ‘ de-SPAC norm. This trend is emblematic of broader market dynamics in the SPAC environment, where some investors prioritize short-term speculation over informed, long-term investment. In recent years, it’s been the norm to compete for the exit door as so many of these SPAC transactions had finance structures surrounding the de-SPAC that encouraged selling. Unlike most SPAC transactions in recent years, we worked diligently to secure prudent closing terms in our merger. We did not allow the issuance of commitment shares or warrants at a zero-cost basis that would otherwise incentivize selling. We did just the opposite. We painfully renegotiated existing sponsor side fees and reduced share issuances to the extent we could.”

Alterity Therapeutics (NASDAQ:ATHE) reported positive Phase 2 ATH434-201 trial topline results, for patients with early-stage Multiple System Atrophy (MSA). The data highlights clinical and biomarker-based improvements that could pave the way for a promising new treatment option for MSA.

Tectonic Therapeutic (NASDAQ: TECX) released positive interim data from their TX45 Phase 1b. TX45 showed promise for patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The interim results show that TX45, a long-acting Fc-relaxin fusion protein, has the potential to improve both left ventricular function and pulmonary hemodynamics—critical factors for managing this complex condition.

NanoVibronix (NASDAQ:NAOV) and Sacks Parente Golf (NASDAQ:SPGC) are trading higher, this morning, on momentum.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KZIA, AMOD, ATHE, TECX, NAOV, SPGC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.